Allo-SCT in relapsed CBF-AML: rethinking the remission requirement

Affiliations

¹ Vanderbilt University Medical Center, Department of Internal Medicine, Division of Hematology and Medical Oncology, Nashville, TN, USA. Kateryna.fedorov@vumc.org.
² Deenanath Mangeshkar Hospital, Department of Clinical Haematology, Pune, Maharashtra, India.
³ The Ottawa Hospital, Division of Hematology Department of Medicine, Ottawa, ON, Canada.

Editorial

Kateryna Fedorov et al. Bone Marrow Transplant. 2025.

. 2025 Jun 7.

doi: 10.1038/s41409-025-02634-x. Online ahead of print.

¹ Vanderbilt University Medical Center, Department of Internal Medicine, Division of Hematology and Medical Oncology, Nashville, TN, USA. Kateryna.fedorov@vumc.org.
² Deenanath Mangeshkar Hospital, Department of Clinical Haematology, Pune, Maharashtra, India.
³ The Ottawa Hospital, Division of Hematology Department of Medicine, Ottawa, ON, Canada.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087–94. - DOI - PubMed
1. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. - DOI - PubMed
1. Darwish C, Farina K, Tremblay D. The core concepts of core binding factor acute myeloid leukemia: current considerations for prognosis and treatment. Blood Rev. 2023;62:101117. - DOI - PubMed
1. Gyurkocza B, Lazarus HM, Giralt S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant. 2017;52:1083–90. - DOI - PubMed
1. Kopinska A, Weglarz P, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, Armatys A, et al. Allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a single-centre experience. Clin Lymphoma Myeloma Leuk. 2023;23:28–39. - DOI - PubMed